FDA Approves Sanofi and Regeneron's Dupixent as First Biologic for COPD

Sep 27, 2024, 01:39 PM

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab), developed by Sanofi ($SNY) and Regeneron ($REGN), as the first-ever biologic medicine for patients with Chronic Obstructive Pulmonary Disease (COPD). This approval marks a significant milestone for the drug, which has already been approved for similar use in China and by European regulators. The approval, announced on Friday, is expected to open a new chapter for Sanofi and Regeneron's blockbuster drug, commonly known as 'smoker's lung' treatment.